syntaxin binding protein 6Genealiases: HSPC156 · amisyn
Q-omics provides the consensus-scored STXBP6 profile across patient tissues and cancer cell-line models. STXBP6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, STXBP6 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, STXBP6 protein abundance shows 23,140 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, LUAD, and GBM as cancer lineages where STXBP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STXBP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STXBP6 survival associations across molecular data types. STXBP6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STXBP6 RNA expression–survival associations across cancer types. High STXBP6 expression shows unfavorable associations in BLCA and LUAD, but favorable associations in LGG, OV, DLBC and LUSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for STXBP6 RNA expression.
This table summarizes STXBP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for STXBP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STXBP6 shows lower tumor expression in LUAD, BLCA, LUSC and BRCA and higher tumor expression in LIHC and UCEC. The LUAD box plot shows higher STXBP6 RNA expression in normal versus tumor tissue (log2 FC = −3.895, t-test p < 0.001).
This table shows molecular features associated with STXBP6 in patient tissues and cancer cell lines. In patient samples, STXBP6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, STXBP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
